NMN for women

NMN for Women: Benefits, Dosage, Menopause, and What Human Studies Show

Woman in her 50s in a sun hat, smiling on a walk through a green garden

NMN has become one of the most talked-about supplements in healthy aging.

The basic reason is simple: your body uses NMN to make NAD+, a coenzyme every cell needs for energy metabolism and other essential cellular processes.

And this is not only a male-biohacker story.

Women have been studied directly. That includes postmenopausal women and women in their 40s and 50s.

Across human research, the clearest and most consistent finding is that taking NMN raises NAD+ or related NAD metabolites*. In women specifically, researchers have also reported a meaningful metabolic effect in a randomized trial, along with early findings involving sleep, fatigue, skin, and hair in smaller studies.

This guide explains what that means for a woman deciding whether NMN belongs in her routine.

See What Women’s Studies FoundNMN for Women in 30 Seconds

Written by

Florian Rivas

Editorial standardsUpdated

46 publicationsPublished full-text scientific publications reviewed
3 women’s studiesPublished intervention studies specifically in women
Human firstHuman studies prioritized
September 2026Evidence reviewed September 2026

NMN for Women in 30 Seconds

  1. What is NMN?

    A molecule your body already uses to make NAD+.

  2. What does human research show most consistently?

    Oral NMN raises NAD+ or related NAD metabolites in human studies*.

  3. Has NMN actually been studied in women?

    Yes. Three published intervention studies in this review were conducted specifically in women.

  4. What was the strongest women-specific finding?

    Improved skeletal-muscle insulin sensitivity in a randomized trial of postmenopausal women with prediabetes.

  5. What amounts have women taken in studies?

    250 mg, 300 mg, and 500 mg per day.

  6. Where does NMN fit best?

    As a daily NAD+ and cellular-health supplement within a broader healthy-aging routine*.

Chapter 01

What Does NMN Do for Women?

NMN gives your body more of a molecule it already uses to make NAD+*.

That is the simplest and most useful answer.

NAD+ is required for the redox reactions cells use to turn nutrients into usable energy. It is also used by enzymes involved in normal cellular signaling and maintenance.

NMN sits one step upstream.

Your body uses NMN as a precursor to make NAD+.

NR is another precursor. NMN vs NR compares the two.

In human studies, oral NMN consistently raises circulating NAD+ or related metabolites*.

That is why the strongest reason to take NMN today is not a vague promise to "reverse aging."

It is much more concrete:

NMN supports the NAD+ pathway by supplying a precursor your body already uses*.

Woman riding a bicycle along a seaside promenade at sunset

What is beta-NMN?

You may also see the term beta-NMN or β-NMN on a label.

Beta-NMN is the beta form of nicotinamide mononucleotide, the form used in many human NMN studies. "Beta" describes the molecule's configuration. It does not mean a stronger dose, a premium version, or a different supplement category.

CELLSHE NMN 500 uses beta-NMN.

NMN → NAD+ → Cellular Processes

  1. You take NMN.

  2. Your body uses NMN to make NAD+.

  3. NAD+ participates in cellular energy metabolism and other NAD+-dependent processes.

NMN does not create a new pathway. It supplies more starting material for one your body already uses.

Chapter 02

Why Are Women Interested in NMN After 40?

Midlife is when many women start paying closer attention to muscle, glucose regulation, recovery, sleep, and long-term health.

Menopause can add another layer to that conversation.

NMN is relevant here because it sits inside cellular metabolism rather than hormone replacement.

Researchers are studying whether increasing NMN availability can support NAD+ biology and influence measurable functions that matter as we age.

That includes metabolism, physical function, sleep, and other outcomes.

The evidence is not equally developed in every area.

But women are no longer absent from the research.

That matters.

Chapter 03 · Women-specific human evidence

What Have Human Studies in Women Actually Found?

Three published intervention studies in the CELLSHE evidence review were conducted specifically in women.

They do not all carry the same weight.

Together, they give us a much clearer starting point than simply saying "NMN has been studied in humans."

Clinician in blue gloves picking a blood sample tube from a rack, with a woman seated in the background

Study 1 · strongest controlled evidence

250 mg/day10 weeks
Randomized · double-blind · placebo-controlled

250 mg/day for 10 Weeks: The Strongest Controlled Evidence

Yoshino et al., Science, 2021

Who
25 postmenopausal women with overweight or obesity and prediabetes.
Design
Randomized, double-blind, placebo-controlled.
What they took
250 mg NMN per day.

What researchers found: NMN improved insulin-stimulated glucose disposal in skeletal muscle and improved muscle insulin-signaling and remodeling endpoints.

Why it matters: This is the most important direct women-specific NMN study in the current evidence base.

It did not only show a change in an NAD+ biomarker.

It found a measurable physiological effect in women.

Because the study was randomized and placebo-controlled, it carries more weight than the smaller uncontrolled women-only studies below.

CELLSHE take: This is the strongest direct evidence so far that NMN can influence a meaningful metabolic process in women.

Study 2

300 mg/day8 weeks
Single-arm · uncontrolled

300 mg/day for 8 Weeks in Postmenopausal Women

Morita et al., Glycative Stress Research, 2022

Who
17 postmenopausal women aged 50–80 enrolled. Sixteen completed the study.
What they took
300 mg NMN per day after breakfast.

What researchers found: The study measured a broad range of biomarkers and subjective outcomes.

Subjective skin, sleep, and fatigue scores showed positive signals during the study.

Estradiol and several other measured hormones did not significantly change.

Why it matters: This study gives us direct information from postmenopausal women.

Its subjective findings are early, but they identify areas worth testing in larger controlled trials.

Study 3

500 mg/day12 weeks
Single-arm · pre/post

500 mg/day for 12 Weeks in Women Aged 40–50

Fukumoto et al., Cosmetics, 2025

Who
15 healthy Japanese women aged 40–50 with hair concerns.
What they took
500 mg NMN per day.

What researchers found: Several hair-related measures changed positively during the study, including selected measures of hair elongation density, shaft diameter, and cuticle condition.

Subjective hair-quality and fatigue measures also improved.

Why it matters: This is direct human evidence in women using 500 mg per day.

The findings are preliminary, but the study is useful both for female-specific research and for understanding the amounts used in published human work.

What do the three studies tell us together?

Women have taken 250 mg, 300 mg, and 500 mg per day in published intervention studies.

The strongest controlled result is metabolic.

Sleep, fatigue, skin, and hair findings are earlier.

That is the hierarchy.

Chapter 04 · The realistic hierarchy

What Are the Most Realistic Benefits of NMN for Women?

NMN is easier to understand when we stop treating every possible outcome as equally established.

For the broader list of studied outcomes, see NMN benefits in human research.

NAD+ Support Is the Strongest Reason to Take NMN

Multiple human trials show that oral NMN raises NAD+ or related metabolites.

This is the most consistent result across the clinical research.

It is also the biological reason NMN is used as a supplement in the first place.

If your goal is to support NAD+ biosynthesis, this is the strongest part of the evidence*.

Metabolic Health Has an Important Women-Specific Result

In the Yoshino randomized trial, 250 mg/day improved skeletal-muscle insulin sensitivity in postmenopausal women with prediabetes.

This matters because researchers observed a physiological effect, not only a biomarker change.

It is the clearest direct women-specific outcome in the current evidence base.

Physical Function Has Promising Human Research

Broader human trials have studied walking, exercise capacity, lower-limb function, and other performance outcomes.

Several trials have reported positive functional signals.

The results vary by population and test, so physical performance is a promising area rather than the primary reason to take NMN.

Sleep and Fatigue Are Interesting Early Signals

Sleep, drowsiness, and fatigue have appeared in several human studies, including research involving postmenopausal women.

These findings are not yet as established as the NAD+ response.

They are still relevant because they relate directly to daily function and quality of life.

Hair Is an Early Women-Specific Research Area

A small women-only study using 500 mg/day reported positive changes in selected hair measures and subjective hair quality.

This is early evidence.

It gives researchers a clear question to test next in a controlled trial.

Reproductive Aging Is Still Mostly a Preclinical Research Field

NMN has produced interesting ovarian and oocyte findings in animal and laboratory research.

That makes reproductive aging an active scientific area.

It does not make NMN a fertility treatment for women.

Chapter 05 · Menopause, estrogen, and HRT

NMN and Menopause: Where Does It Actually Fit?

NMN is relevant to the menopause conversation for one important reason:

Some of the direct human research has been conducted in postmenopausal women.

The useful question is where NMN fits.

NMN is not a hormone.

It supplies a precursor your body uses to make NAD+*.

That places it on the healthy-aging and cellular-health side of midlife rather than the hormone-replacement side.

Two women with gray hair laughing over coffee at an outdoor café

During perimenopause

What About NMN During Perimenopause?

NMN can fit into the healthy-aging side of a perimenopause routine by supporting the NAD+ pathway*.

Current human studies have not tested NMN as a treatment for hot flashes or other perimenopause symptoms.

Use NMN for NAD+ support*, not as a substitute for symptom-specific care.

Estrogen

Does NMN Increase Estrogen?

A small eight-week study in postmenopausal women measured estradiol directly.

Estradiol did not significantly change.

So the reason to take NMN is not to raise estrogen.

During menopause

Can NMN Help During Menopause?

Think of NMN as part of the healthy-aging side of midlife*.

The strongest direct postmenopausal evidence involves skeletal-muscle insulin sensitivity.

If your primary goal is treating hot flashes, night sweats, vaginal symptoms, or another menopause symptom, that is a different treatment decision.

The two ideas are easy to separate:

Treat menopause symptoms appropriately.
Support healthy aging appropriately.

HRT

Can I Take NMN With HRT?

Human research has not established a special benefit from combining NMN with hormone therapy.

They also target very different biological systems.

If you use prescription hormone therapy, include NMN on the supplement list you review with the clinician managing your treatment.

Chapter 06 · Amounts used in human research

How Much NMN Should a Woman Take?

Online NMN dosing can become complicated very quickly.

The human research gives us a simpler starting point.

A glass of water next to a plain white supplement bottle on a bedside table
250 mg/day10 weeks

Randomized postmenopausal metabolic trial.

300 mg/day8 weeks

Postmenopausal women.

500 mg/day12 weeks

Healthy women aged 40–50.

Broader human studies have tested a wider range of daily amounts.

There is no validated formula that assigns women a different dose simply because they are women.

There is also no validated dose-by-age or dose-by-body-weight formula.

500 mg

Is 500 mg a Sensible NMN Amount?

500 mg is a research-grounded human serving.

It has been used directly in a published women-only study.

It also sits comfortably inside the wider range studied in adult NMN research.

That does not make 500 mg the only possible amount.

It makes it a serious, clearly disclosed serving rather than a marketing number.

Daily routine

When Should You Take NMN?

Most human NMN studies use daily dosing.

For a real-world routine, consistency matters more than creating an elaborate timing protocol.

Morning is a simple habit anchor.

Follow the directions on the product you use.

There is no convincing human evidence that one precise hour is required for NMN to work.

For morning, evening and food questions, see how and when to take NMN.

Bottom line: 500 mg is within the published women-specific and broader human research range.

Chapter 07 · The current human safety picture

Is NMN Safe for Women?

Short-term human safety data are generally reassuring.

A 2026 systematic review and meta-analysis of randomized NMN studies by Yang and colleagues found no significant increase in overall adverse events, serious adverse events, withdrawals due to adverse events, or the major system-specific adverse-event categories assessed.

Human studies have tested NMN across multiple doses for periods ranging from days to several months.

Across those trials, NMN has generally been well tolerated.

Woman with gray hair reading a supplement bottle and its leaflet at home

Reported effects

What Side Effects Have Been Reported?

When adverse events have occurred in trials, they have generally been mild.

Across the larger randomized evidence base, adverse events were not significantly more common overall with NMN than with control.

Evidence horizon

What About Long-Term Use?

Most human NMN research is still measured in weeks or months.

That gives us useful short-term safety information.

Multi-year human safety data are not yet available.

Pregnancy and breastfeeding

Pregnancy and Breastfeeding

NMN has not been adequately studied during pregnancy or breastfeeding.

Do not start it in those situations without specific medical guidance.

Medication

Prescription Medications

If you take prescription medication or are under medical care, show your clinician the complete supplement label before adding NMN.

A transparent label makes that conversation much easier.

Chapter 08 · The decision

Should NMN Be Part of Your Routine?

This is the decision the page should help you make.

NMN may be a good fit to consider if

  • You are interested in healthy aging and cellular health.
  • Supporting NAD+ biology is one of your priorities*.
  • You prefer a simple daily supplement rather than an elaborate stack.
  • You want an ingredient studied directly in humans and in women.
  • You care about a clearly disclosed dose and independent testing.
  • You are comfortable with a supplement whose strongest evidence is biological and metabolic rather than a stimulant-style feeling.

If you want a simple, human-studied NAD+ precursor as part of a broader healthy-aging routine, NMN is a reasonable supplement to consider*.

CELLSHE decision tool

The NMN Decision Guide for Women

What to know before you decide whether NMN belongs in your routine.

01What NMN does

NMN is a precursor your body uses to make NAD+, a coenzyme required for cellular energy metabolism and other NAD+-dependent processes*.

02What human research shows most consistently

Oral NMN raises NAD+ or related metabolites in human studies.

03What women-specific research has found

The strongest women-specific controlled trial found improved skeletal-muscle insulin sensitivity in postmenopausal women with prediabetes.

04Amounts used in women-specific studies
250 mg/day300 mg/day500 mg/day
05NMN may fit your goal if
  • You want to support NAD+ biology*.
  • You want a simple healthy-aging supplement.
  • You prefer a clearly disclosed single ingredient.
  • You value human research and transparent testing.
06Before you buy
  • Exact beta-NMN amount is shown.
  • No proprietary blend hides the dose.
  • Finished product is third-party tested.
  • COA is available.
  • Dose sits within published human research.
  • Formula matches what you actually want.
07Important safety check

Pregnant or breastfeeding: NMN is not adequately studied.
Prescription medication or medical care: review the complete label with your clinician.

08The simple take

NMN is best understood as a daily NAD+ precursor within a broader healthy-aging routine*.

For the full evidence library and research updates: cellshe.com/pages/nmn-for-women*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Chapter 09 · Before you buy

How to Choose an NMN Supplement

Once you decide that you want NMN, choosing the product should not be complicated.

Ignore the biggest front-label number.

Check these instead.

Gloved hand holding a capsule with tweezers above a dish of capsules in a laboratory

How Much Actual NMN Is in One Serving?

Look for the amount of NMN itself.

Not the weight of a blend.

Not a proprietary complex.

Not a front-label number that includes other ingredients.

Is It Beta-NMN?

Beta-NMN is the beta form of nicotinamide mononucleotide used in many human NMN studies.

The word "beta" does not mean a stronger dose.

It tells you which molecular form is in the product.

Is the Dose Clearly Disclosed?

You should know exactly how much beta-NMN you are taking before you buy.

Has the Finished Product Been Independently Tested?

Supplements are only useful if the bottle contains what the label says it contains.

Look for third-party finished-product testing from an appropriately accredited laboratory.

Can You See a Certificate of Analysis?

A COA lets you inspect testing instead of relying only on marketing copy.

Does the Formula Match What You Actually Want?

If you want NMN, a single-ingredient NMN formula is the simplest option.

A larger stack only makes sense if you intentionally want the additional ingredients.

The CELLSHE formula

Why CELLSHE Uses 500 mg of Beta-NMN

CELLSHE publishes this guide and also makes NMN 500.

CELLSHE NMN 500 provides 500 mg of beta-NMN in one capsule.

We chose 500 mg for a straightforward reason.

It is a substantial amount with direct human research context behind it.

A women-only human study used 500 mg per day for 12 weeks.

And 500 mg sits within the wider range used across published adult NMN research.

That gives us a clear research-grounded serving without turning the product into a dose-escalation contest*.

CELLSHE NMN 500 bottle and capsules on rust linen
CELLSHE NMN 500. One capsule provides 500 mg beta-NMN.

Inside CELLSHE NMN 500

One active. One capsule. A research-grounded amount.

For the woman who wants NMN without building an elaborate supplement stack, this is what we built.

500 mg beta-NMNOne active ingredient
One capsule per day30 capsules · 30 daily servings
Third-party testedISO/IEC 17025-accredited laboratory
Certificate of AnalysisTesting you can inspect
Non-hormonalA simple NAD+ precursor formula*
60-Day GuaranteeKeep the bottle, no questions asked.

Choose how you want to order

One-time purchase

$49

One bottle · 30 daily servings

Subscribe & Save

$39/month

Free U.S. subscription shipping · Priority access to the CELLSHE Circle · Pause, skip, or cancel directly in your account

View Full Product Details
CELLSHE NMN 500 Certificate of Analysis from third-party laboratory testing
Recent CELLSHE NMN 500 Certificate of Analysis. Select the image to inspect it at full size.

Testing and quality proof

Testing you can inspect.

CELLSHE NMN 500 is third-party tested through an ISO/IEC 17025-accredited laboratory. The Certificate of Analysis is available so you can inspect the testing directly.

Finished-product testingThe bottle is tested, not only the ingredient specification.
COA availableThe testing record is visible instead of hidden behind marketing copy.
Clearly disclosed dose500 mg beta-NMN per capsule.
Simple formulaOne active ingredient, with no proprietary blend hiding the amount.

Read the CELLSHE testing standard

For readers who want to inspect the evidence

Want to Audit the Science Yourself?

You do not need to read 46 scientific publications to decide whether NMN interests you.

But you should be able to if you want to.

CELLSHE reviewed 46 published full-text scientific publications for this guide.

The library includes women-specific human intervention studies, broader human NMN research, systematic reviews and meta-analyses, human context and mechanism, and female reproductive preclinical research.

Every entry links directly to the source and shows who or what was studied, the dose, duration, design, and the result that matters for this page.

46full-text publications 3women-specific interventions 18broader human interventions 13syntheses 4human context 8female preclinical

Human Studies in Women

Direct intervention evidence in women3 publications
Women RCT Yoshino et al., Science, 2021 Open source

Who / scope 25 postmenopausal women with overweight/obesity and prediabetes · Dose NMN 250 mg/day · Duration 10 weeks · Design Randomized, double-blind, placebo-controlled

NMN improved skeletal-muscle insulin sensitivity and insulin signaling/remodeling endpoints in this specific population

Women study Morita et al., Glycative Stress Research, 2022 Open source

Who / scope 17 postmenopausal women aged 50–80; 16 completed · Dose NMN 300 mg/day, after breakfast · Duration 8 weeks · Design Single-arm, uncontrolled

Subjective skin, sleep, and fatigue scores showed positive signals. Estradiol and several other measured hormones did not significantly change.

Women study Fukumoto et al., Cosmetics, 2025 Open source

Who / scope 15 healthy Japanese women aged 40–50 with hair concerns · Dose NMN 500 mg/day · Duration 12 weeks · Design Single-arm pre/post intervention

Selected hair measures changed positively, including hair elongation density, shaft diameter, and cuticle measures. Subjective hair-quality and fatigue measures also improved

Broader Human NMN Research

Controlled, uncontrolled, safety, dose, and mechanistic human intervention studies18 publications
Human study Irie et al., Endocrine Journal, 2020 Open source

Who / scope 10 healthy men · Dose Single 100, 250 or 500 mg doses · Duration Acute, hours · Design Acute dose-escalation / pharmacokinetic safety study

No major acute safety signal was identified, and the study characterized circulating metabolites after oral NMN

Human controlled Liao et al., Journal of the International Society of Sports Nutrition, 2021 Open source

Who / scope 48 amateur runners; female representation small · Dose Placebo, 300, 600 or 1200 mg/day · Duration 6 weeks · Design Randomized, double-blind, placebo-controlled with exercise training

Some ventilatory-threshold and submaximal performance measures favored medium/high-dose NMN. A universal VO2max or peak-performance effect was not demonstrated

Human controlled Okabe et al., Frontiers in Nutrition, 2022 Open source

Who / scope 30 healthy adults; both sexes · Dose 250 mg/day · Duration 12 weeks · Design Randomized, double-blind, placebo-controlled

Whole-blood NAD+ increased, with no major safety or laboratory concerns. The paper did not demonstrate a broad physiological consequence of the NAD+ rise

Human controlled Fukamizu et al., Scientific Reports, 2022 Open source

Who / scope 31 analyzed healthy adults, both sexes, 20–65 years · Dose 1250 mg/day · Duration 4 weeks · Design Randomized, double-blind, placebo-controlled

No severe adverse events or clinically concerning safety trends were reported over four weeks

Human controlled Kim et al., Nutrients, 2022 Open source

Who / scope 108 older adults, men and women · Dose 250 mg/day · Duration 12 weeks · Design Randomized, double-blind, placebo-controlled; morning/afternoon groups

Some lower-limb-function and drowsiness/timing signals were reported. Sleep, fatigue, and physical-function results were not uniformly positive across outcomes

Human controlled Igarashi et al., npj Aging, 2022 Open source

Who / scope Healthy older men, ≥65 · Dose 250 mg/day · Duration Intended 12 weeks · Design Randomized, double-blind, placebo-controlled

Blood NAD-related metabolites increased. Nominal gait-speed and left-grip signals were reported, with no clear body-composition benefit

Human controlled Huang, Frontiers in Aging, 2022 Open source

Who / scope 66 healthy middle-aged/older adults; 62 completed · Dose 300 mg/day · Duration 60 days · Design Multicentre randomized, double-blind, placebo-controlled

NAD+/NADH and some exploratory health outcomes were reported favorably

Human controlled Pencina et al., Journals of Gerontology Series A, 2023 Open source

Who / scope 32 overweight/obese adults, 55–80; 16 men, 16 women · Dose 1000 mg once daily or 1000 mg twice daily · Duration 14 days · Design Double-blind, placebo-controlled, sex-stratified

Circulating NMN/NAD metabolites increased. No significant sex difference in NMN exposure was detected in this small study

Human controlled Yi et al., GeroScience, 2023 Open source

Who / scope 80 healthy middle-aged adults, substantial female representation · Dose 300, 600, 900 mg/day · Duration 60 days · Design Randomized multicenter double-blind placebo-controlled

Blood NAD increased at all NMN doses. Six-minute-walk and SF-36 differences were reported; HOMA-IR did not significantly differ from placebo

Human controlled Katayoshi et al., Scientific Reports, 2023 Open source

Who / scope 36 healthy middle-aged adults, both sexes · Dose 250 mg/day · Duration 12 weeks · Design Randomized, double-blind, placebo-controlled

Serum nicotinamide increased. There was no significant between-group arterial-stiffness effect

Human controlled Akasaka et al., Geriatrics & Gerontology International, 2023 Open source

Who / scope 14 older men with diabetes and impaired physical performance; mean age ~81 · Dose 250 mg/day · Duration 24 weeks · Design Placebo-controlled, double-blind

NMN was tolerated. Grip strength, walking speed, and exploratory outcomes did not significantly improve between groups

Human study Yamane et al., Clinical Nutrition ESPEN, 2023 Open source

Who / scope 11 healthy volunteers · Dose 250 mg each morning · Duration 12 weeks · Design Single-arm

Plasma NMN/NAD-related metabolites rose, with a postprandial insulin signal and high inter-individual variability

Human controlled Pencina et al., Journal of Clinical Endocrinology & Metabolism, 2023 Open source

Who / scope 30 overweight/obese adults ≥45 years, randomized and sex-stratified · Dose MIB-626 1000 mg twice daily = 2000 mg/day · Duration 28 days · Design Double-blind, randomized, placebo-controlled

NAD/metabolome measures increased substantially. Exploratory weight, DBP, and lipid changes were reported, while several fat and insulin-sensitivity endpoints did not significantly improve

Human study Qiu et al., Signal Transduction and Targeted Therapy, 2023 Open source

Who / scope Human participants · Dose 800 mg/day NMN plus lifestyle vs lifestyle alone · Duration Paper contains a reporting inconsistency between the intervention description and results timing; this must be treated cautiously · Design Human open randomized lifestyle-modification comparison embedded within extensive mouse/cell reverse-translational research

PBMC NAD+ increased and vascular/BP improvements were reported in the very small human intervention. The study included a lifestyle co-intervention and reporting complexity

Human study Yamaguchi et al., Endocrine Journal, 2024 Open source

Who / scope Healthy Japanese men 40–60; 9 completed active NMN phase · Dose 250 mg/day before breakfast · Duration 8 weeks active NMN · Design Single-center, single-arm/open-label with placebo run-in

PBMC NAD+ rose. Sleep quality, glucose/insulin measures, and body composition were broadly unchanged

Human controlled Morifuji et al., GeroScience, 2024 Open source

Who / scope 60 older adults · Dose 250 mg/day · Duration 12 weeks · Design Double-blind randomized placebo-controlled

Blood NAD/metabolites increased. The primary stepping-test endpoint was not significantly improved; secondary walking-time and some sleep measures were favorable

Human controlled Nakajima et al., Fundamental Toxicological Sciences, 2025 Open source

Who / scope 30 healthy men and women aged 20–64 · Dose 750 or 1500 mg/day · Duration 4 weeks · Design Randomized, double-blind, placebo-controlled

No clinically problematic laboratory or adverse-event pattern was reported. Blood NAD increased; telomere length did not meaningfully change

Human controlled Yang et al., Journal of the International Society of Sports Nutrition, 2026 Open source

Who / scope 11 untrained young men, mean age ~22.8 · Dose 1200 mg/day · Duration 7 days per condition, with washout · Design Randomized, placebo-controlled, counterbalanced crossover

NMN altered post-exercise inflammatory signaling and also delayed selected myogenic-resolution signals in this very small young-male mechanistic study

Systematic Reviews and Syntheses

Pooled evidence, critical reviews, and regulatory context13 publications
Synthesis Song et al., Advances in Nutrition, 2023 Open source

Who / scope Published human NMN clinical trials · Dose Multiple studies · Duration Multiple studies · Design Review / evidence update

Maps the early human NMN trial landscape and separates published human outcomes from preclinical enthusiasm

Synthesis Chen et al., Current Diabetes Reports, 2024 Open source

Who / scope 8 RCTs, 342 adults, about 49% female · Dose 250–2000 mg/day · Duration 14 days–12 weeks · Design Systematic review and meta-analysis of RCTs

Across eight RCTs, pooled fasting glucose, fasting insulin, HbA1c, HOMA-IR, and lipid outcomes did not significantly improve

Synthesis Yang et al., Nutrients, 2026 Open source

Who / scope 15 randomized adult NMN studies · Dose 250–2000 mg/day · Duration 14 days–24 weeks · Design Systematic review and meta-analysis

Across 15 randomized studies, pooled safety was generally reassuring for studied durations. Broad weight, glucose, HbA1c, lipid, and systolic-BP benefits were not consistent

Synthesis Prokopidis et al., Journal of Cachexia, Sarcopenia and Muscle, 2025 Open source

Who / scope Human NMN and NR trials assessing muscle outcomes · Dose Multiple studies · Duration Multiple studies · Design Systematic review and meta-analysis

Pooled analyses did not show significant improvements in skeletal muscle index, handgrip strength, gait speed, or five-times-chair-stand

Synthesis Zhang et al., Nutrients, 2026 Open source

Who / scope 349 participants across 10 RCTs / 11 intervention arms · Dose Multiple studies · Duration Multiple studies · Design Systematic review and meta-analysis

No robust broad systolic-BP effect was found. Modest diastolic-BP signals and subgroups require cautious interpretation

Synthesis Freeberg et al., Journals of Gerontology: Series A, 2023 Open source

Who / scope Human NAD+-boosting compound studies · Dose Multiple studies · Duration Multiple studies · Design Review of human evidence

NAD-related metabolites can be raised in humans, while physiological benefits remain inconsistent across heterogeneous, generally small trials

Synthesis Bhasin et al., Endocrine Reviews, 2023 Open source

Who / scope Human and translational NAD biology literature · Dose Not an intervention trial · Duration Not applicable · Design High-authority scientific review

High-authority review of NAD biology, pharmacology, and translation that emphasizes the gap between preclinical findings and established human anti-aging efficacy

Synthesis Vinten et al., Nature Metabolism, 2025 Open source

Who / scope Human NAD+ precursor supplementation literature · Dose Multiple studies · Duration Multiple studies · Design Clinical evidence review

Human age-related NAD decline is not uniformly demonstrated across all tissues or populations. Tissue-specific biology and limited clinical data matter

Synthesis Peluso et al., Nutrients, 2022 Open source

Who / scope Human evidence on age and NAD+ biology · Dose Not an intervention trial · Duration Not applicable · Design Critical review

Human evidence for a universal age-related NAD+ decline is sparse, tissue-specific, and often cross-sectional

Synthesis EFSA NDA Panel, 2026 Open source

Who / scope Specific beta-NMN novel-food safety assessment · Dose 300 mg/day use condition for the assessed ingredient · Duration Regulatory context · Design EFSA scientific opinion

Regulatory safety context for a specific beta-NMN novel-food ingredient. Its 300 mg/day use condition is not evidence of an optimal NMN dose

Synthesis Noh et al., Journal of Assisted Reproduction and Genetics, 2026 Open source

Who / scope Preclinical NMN interventions plus human oocyte transcriptomics · Dose Preclinical exposures · Duration Multiple studies · Design Systematic review and transcriptomic analysis

The intervention studies identified by the systematic review were preclinical. Human oocyte transcriptomics do not constitute a human NMN supplementation efficacy trial

Synthesis Cordone et al., Biology of Reproduction, 2026 Open source

Who / scope Ovarian NAD metabolism and NAD-boosting literature · Dose Multiple / preclinical · Duration Multiple studies · Design Scientific review

Reviews ovarian NAD metabolism and NAD boosters. Well-designed human studies directly evaluating fertility effects remain lacking

Synthesis Liang et al., Immunity & Ageing, 2023 Open source

Who / scope Ovarian aging and NAD biology literature · Dose Multiple / preclinical · Duration Multiple studies · Design Scientific review

Reviews NAD+ metabolism in ovarian aging. Translational human supplementation evidence remains limited

Human Context and Mechanism

Human biology that helps interpret NMN without becoming supplementation efficacy evidence4 publications
Human context Clement et al., Rejuvenation Research, 2019 Open source

Who / scope Healthy humans spanning young to older adulthood · Dose No NMN intervention · Duration Cross-sectional · Design Cross-sectional metabolomics

Plasma NAD+, NADP+, and related metabolites showed age associations, while plasma NMN did not show a simple universal age decline

Human context Massudi et al., PLOS One, 2012 Open source

Who / scope Human skin tissue spanning newborn to older age · Dose No NMN intervention · Duration Cross-sectional · Design Cross-sectional tissue study

Human skin tissue showed age-related associations in NAD biology and oxidative-stress markers. This is tissue-specific, cross-sectional evidence

Human context Smits et al., Human Reproduction, 2023 Open source

Who / scope Human ovarian tissue biopsies and oocytes · Dose No NMN intervention · Duration Human tissue study · Design Human mechanistic study

Advanced maternal age was associated with oxidative damage and mitochondrial dysfunction in human ovarian tissue and oocytes

Human context Endocrine Society Scientific Statement, 2023 Open source

Who / scope Human endocrine aging and menopause evidence · Dose No NMN intervention · Duration Authoritative context · Design Endocrine Society scientific statement

Authoritative human context on endocrine aging, menopause, ovarian senescence, and hormone therapy. It is not NMN efficacy evidence

Female Reproductive Preclinical Research

Animal and laboratory evidence kept separate from human supplementation evidence8 publications
Preclinical Bertoldo et al., Cell Reports, 2020 Open source

Who / scope Aged female mice · Dose NMN, including chronic drinking-water and acute experiments · Duration Preclinical · Design Mouse study

In aged female mice, NMN improved selected measures of oocyte NAD(P)H, oocyte quality, embryo development, and fertility

Preclinical Uddin et al., Scientific Reports, 2017 Open source

Who / scope Female mouse offspring / maternal-obesity model · Dose High-dose injected NMN · Duration Preclinical · Design Mouse study

In a maternal-obesity mouse model, high-dose injected NMN affected metabolic, liver, and adiposity outcomes

Preclinical Wang et al., Cell Proliferation, 2022 Open source

Who / scope High-fat-diet obese female mice · Dose Preclinical NMN exposure · Duration Preclinical · Design Mouse study

In obese female mice, NMN improved selected oocyte mitochondrial, oxidative-stress, spindle, DNA-damage, and ovarian-inflammatory outcomes

Preclinical Jiang et al., Cell Proliferation, 2023 Open source

Who / scope Mouse environmental-toxin reproductive model · Dose Preclinical NMN exposure · Duration Preclinical · Design Mouse study

In a mouse environmental-toxin model, NMN mitigated mitochondrial dysfunction, oxidative stress, DNA damage, apoptosis, and oocyte defects

Preclinical Guo et al., Nutrition & Diabetes, 2024 Open source

Who / scope Female mice with type 1 diabetes · Dose Preclinical NMN exposure · Duration Preclinical · Design Mouse study

In female mice with type 1 diabetes, NMN improved selected oocyte maturation and quality outcomes

Preclinical Li et al., PLOS One, 2023 Open source

Who / scope Porcine oocytes · Dose Preclinical beta-NMN exposure · Duration Preclinical · Design Non-human oocyte study

In porcine oocytes, beta-NMN improved selected oxidative, mitochondrial, apoptotic, and embryo-development outcomes

Preclinical Xu et al., Antioxidants, 2023 Open source

Who / scope Vitrified bovine oocytes in vitro · Dose Preclinical beta-NMN exposure · Duration Preclinical · Design In vitro oocyte study

In vitrified bovine oocytes, beta-NMN improved selected survival, developmental, and oxidative-stress outcomes

Preclinical Shen et al., Journal of Ovarian Research, 2025 Open source

Who / scope Female mice exposed to cyclophosphamide · Dose Preclinical NMN exposure · Duration Preclinical · Design Mouse chemotherapy model

In chemotherapy-exposed female mice, NMN improved selected ovarian reserve, NAD+, oxidative-stress, DNA-damage, apoptosis, and embryo-development outcomes

The evidence groups are separated on purpose. A human intervention study, a review, a human mechanistic paper, and a mouse or cell study answer different questions. The first group is open because direct evidence in women is the priority for this page.

Evidence methodology

How We Built This Guide

This page starts with human evidence.

Women-specific human trials receive priority when answering a question specifically about women.

Broader human research is used to understand NAD+ response, dosing, safety, and outcomes that have not yet been studied adequately in women-only trials.

Animal and laboratory research is kept separate from human evidence.

Conference abstracts, unpublished trials, registry-only studies, and thin evidence are excluded from the public 46-publication corpus.

We also record study design, population, dose, duration, important endpoints, and relevant commercial relationships.

The goal is simple: make the evidence easy to understand first, and easy to audit second.

Woman reviewing handwritten notes next to her laptop at a wooden table

Evidence order

What carries the most weight?

For a women-specific question, direct evidence in women comes first. Better-controlled human evidence carries more weight than uncontrolled or preclinical findings.

  1. Randomized, placebo-controlled human trials in women
  2. Other human intervention studies
  3. Systematic reviews and meta-analyses
  4. Human mechanistic or contextual studies
  5. Animal and laboratory studies

When results differ, we favor better-controlled designs, more direct evidence in women, larger or longer human studies, and systematic syntheses over isolated small trials.

Audit all 46 publications · See CELLSHE Science

Common questions

Frequently Asked Questions About NMN for Women

Short answers to the questions women most often need before deciding whether NMN fits their routine.

Is NMN good for women over 40?

NMN can be a reasonable healthy-aging supplement for women over 40 who want to support NAD+ biosynthesis*. Women in their 40s and 50s have been studied directly, and 500 mg/day has been used in a women-only study.

Is NMN good for women over 50?

Women over 50 are represented in published NMN research, including postmenopausal women. The strongest women-specific controlled trial studied postmenopausal women and found improved skeletal-muscle insulin sensitivity after 10 weeks.

Does NMN raise NAD+?

Yes. This is the most consistent finding across human NMN trials. Multiple controlled studies have found higher blood NAD+ or related metabolites after oral NMN.

What is beta-NMN?

Beta-NMN, or β-NMN, is the beta form of nicotinamide mononucleotide used in many human NMN studies. “Beta” describes the molecule's configuration. It does not mean a stronger or higher-dose version of NMN.

Will I feel NMN working?

Possibly, but NMN should not be expected to feel like caffeine.

Its strongest human evidence involves measured biological changes rather than an immediate stimulant effect.

Some smaller studies have reported changes in sleep or fatigue, so individual experience can differ.

See what to expect from NMN for realistic results from human studies.

How long does NMN take to work?

Blood NAD-related measures have changed within weeks in human studies.

That does not mean every person will notice a subjective change on the same timeline.

Think of NMN as a consistent daily routine rather than a same-day supplement*.

The study timeline is in how long NMN takes to work.

Is 500 mg of NMN a lot?

500 mg sits within the range studied in humans.

It has also been used directly in a women-only study.

That makes it a research-grounded daily amount, not an arbitrary front-label number*.

Does NMN increase estrogen?

A small study in postmenopausal women measured estradiol directly and did not find a significant increase.

NMN is used as an NAD+ precursor, not as an estrogen supplement.

Can NMN help with menopause?

NMN has been studied in postmenopausal women, including in a randomized metabolic trial.

Its role is better understood as cellular and healthy-aging support* than as a treatment for menopause symptoms.

Can I take NMN with HRT?

Human research has not established a special combination benefit from NMN plus hormone therapy.

If you use prescription HRT, review the complete supplement label with the clinician managing your treatment.

Does NMN help with weight loss?

Weight loss is not an established NMN effect in human trials.

If weight loss is your main goal, choose an approach designed for that goal.

Does NMN improve fertility?

Most intervention research involving NMN and ovarian aging is still preclinical.

NMN is not an established fertility treatment.

Is NMN safe?

Short-term human evidence is generally reassuring.

A 2026 pooled analysis of randomized trials found no significant increase in overall or serious adverse events compared with control.

Longer-term human data are still accumulating.

The decision in plain English

The Bottom Line on NMN for Women

NMN becomes much easier to understand once you separate the core evidence from the longevity noise.

Your body uses NMN to make NAD+*.

Taking NMN raises NAD+ or related metabolites in human studies.

Women have been studied directly.

The strongest women-specific trial found improved skeletal-muscle insulin sensitivity in postmenopausal women with prediabetes.

Women-specific studies have used 250 mg, 300 mg, and 500 mg per day.

And if you want a straightforward NMN product, 500 mg of beta-NMN in one transparent, independently tested capsule is a strong research-grounded option*.

CELLSHE NMN 500 was built around exactly that idea.

Want to compare NMN with creatine or other evidence-reviewed supplements? Browse the CELLSHE Supplement Guides for Women.

CELLSHE NMN 500

A simple one-capsule NMN routine.

500 mg beta-NMN One capsule Third-party tested COA available 60-Day Guarantee

First order covered by CELLSHE's 60-Day Guarantee under the current Refund Policy.

Current CELLSHE offer

Start your NMN routine.

$49 one-time
$39/month with Subscribe & Save

Subscription includes free U.S. shipping and priority access to the CELLSHE Circle under current subscription terms. Pause, skip, or cancel.

See NMN 500

From the Journal

Go deeper on NMN and NAD+

See all NMN and NAD+ articles

Core scientific sources

References

These 20 sources are the core references behind the main decision points on this page. The complete locked review contains 46 published full-text publications.

  1. Yoshino M, et al. Science. 2021. Randomized trial in postmenopausal women

    doi:10.1126/science.abe9985

  2. Morita Y, et al. Glycative Stress Research. 2022. Postmenopausal women

    doi:10.24659/gsr.9.2_33

  3. Fukumoto S, et al. Cosmetics. 2025. Women aged 40–50, 500 mg/day

    doi:10.3390/cosmetics12050204

  4. Okabe K, et al. Frontiers in Nutrition. 2022. Human randomized trial

    doi:10.3389/fnut.2022.868640

  5. Yi L, et al. GeroScience. 2023. 300, 600, and 900 mg/day

    doi:10.1007/s11357-022-00705-1

  6. Kim M, et al. Nutrients. 2022. Older adults, timing and function

    doi:10.3390/nu14040755

  7. Morifuji M, et al. GeroScience. 2024. Older adults, NAD+ and function

    doi:10.1007/s11357-024-01204-1

  8. Chen F, et al. Current Diabetes Reports. 2024. Systematic review and meta-analysis

    doi:10.1007/s11892-024-01557-z

  9. Yang W, et al. Nutrients. 2026. Safety and metabolism systematic review and meta-analysis

    doi:10.3390/nu18142251

  10. Prokopidis K, et al. Journal of Cachexia, Sarcopenia and Muscle. 2025. Muscle outcomes meta-analysis

    doi:10.1002/jcsm.13799

  11. Pencina KM, et al. Journals of Gerontology: Series A. 2023. Human sex-stratified pharmacology

    doi:10.1093/gerona/glac049

  12. Fukamizu Y, et al. Scientific Reports. 2022. 1250 mg/day safety study

    doi:10.1038/s41598-022-18272-y

  13. Akasaka H, et al. Geriatrics & Gerontology International. 2023. 24-week human trial

    doi:10.1111/ggi.14513

  14. Liao B, et al. Journal of the International Society of Sports Nutrition. 2021. NMN with exercise training

    doi:10.1186/s12970-021-00442-4

  15. Bhasin S, et al. Endocrine Reviews. 2023. NAD biology and translation review

    doi:10.1210/endrev/bnad019

  16. Peluso A, et al. Nutrients. 2022. Human NAD+ and aging review

    doi:10.3390/nu14010101

  17. Noh H, et al. Journal of Assisted Reproduction and Genetics. 2026. Ovarian-aging evidence synthesis

    doi:10.1007/s10815-025-03720-1

  18. Smits MAJ, et al. Human Reproduction. 2023. Human ovarian context

    doi:10.1093/humrep/dead177

  19. Bertoldo MJ, et al. Cell Reports. 2020. Preclinical female reproductive evidence

    doi:10.1016/j.celrep.2020.01.058

  20. Cappola AR, et al. Journal of Clinical Endocrinology & Metabolism. 2023. Endocrine aging and menopause context

    doi:10.1210/clinem/dgad225

Search the complete 46-publication evidence library

Medical and product information

CELLSHE products are dietary supplements intended for healthy adults. This page provides general education and does not replace professional medical advice, diagnosis, or treatment. Consult your healthcare provider before starting a new supplement, especially if you are pregnant, nursing, take medications, use prescription hormone therapy, have a medical condition, or are under medical care. Not for use by individuals under 18 years of age.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. The 60-Day Guarantee is governed by the current Refund Policy.